Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics to Sell $17.5M in Common Stock Through Direct Offering

NEW YORK — Cancer Genetics said on Wednesday that it has signed agreements to sell roughly $17.5 million of its common stock to unnamed institutional investors.

According to the Rutherford, New Jersey-based cancer drug-discovery services provider, it will issue approximately 2.7 million shares of stock at $6.30 apiece in a registered direct offering priced at-the-market under Nasdaq rules. It expects the offering, which is being underwritten by HC Wainwright, to close early next week.

Cancer Genetics said it will use the proceeds for general corporate purposes, including working capital and capital expenditures. The proceeds are expected to be available following the company's planned merger with Stemonix. 

Earlier this year, Cancer Genetics signed agreements to sell $10 million in stock and warrants to institutional and accredited investors. 

During mid-morning trading on the Nasdaq, shares of Cancer Genetics were down 19 percent at $6.95.


The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.